

1     **Clinical manifestations of patients with Coronavirus Disease 2019 (COVID-**  
2                                   **19) attending at hospitals in Bangladesh**

3

4     Md. Shahed Morshed<sup>1</sup>, Abdullah Al Mosabbir<sup>2</sup>, Prodipta Chowdhury<sup>3</sup>, Sheikh Mohammad.  
5     Ashadullah<sup>4</sup> and Mohammad Sorowar Hossain<sup>2,5\*</sup>

6

7     <sup>1</sup>Kurmitola general hospital, Dhaka, Bangladesh

8     <sup>2</sup>Department of Emerging and Neglected Diseases, Biomedical Research Foundation, Dhaka,  
9     Bangladesh

10    <sup>3</sup>Keshabpur upazilla health complex, Jessore, Bangladesh

11    <sup>4</sup>Shailkupa upazilla health complex, Jhenaidah, Bangladesh

12    <sup>5</sup>School of Environment and Life Sciences, Independent University, Bangladesh (IUB),  
13    Dhaka, Bangladesh

14

15    **Running Title:** Clinical manifestations of COVID-19 patients in Bangladesh

16

17    **Corresponding author**

18    Mohammad Sorowar Hossain, Biomedical Research Foundation, Dhaka, Bangladesh

19    E-mail:[sorowar.hossain@brfbd.org](mailto:sorowar.hossain@brfbd.org)

20

21    **Key words:** COVID-19, Clinical manifestation, Pandemic, Bangladesh, Dhaka

22

## 23 **Abstract**

24 Bangladesh is in the rising phase of the ongoing pandemic of the coronavirus disease 2019  
25 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).  
26 The scientific literature on clinical manifestations of COVID-19 patients from Bangladesh is  
27 scarce. This study aimed to report the sociodemographic and clinical characteristics of  
28 patients with COVID-19 in Bangladesh. We conducted a cross-sectional study at three  
29 dedicated COVID-19 hospitals. The severity of the COVID-19 cases was assessed based on  
30 the WHO interim guidance. Data were collected only from non-critical COVID-19 patients as  
31 critical patients required immediate intensive care admission making them unable to respond  
32 to the questions. A total of 103 RT-PCR confirmed non-critical COVID-19 patients were  
33 enrolled. Most of the patients (71.8%) were male. Mild, moderate and severe illness were  
34 assessed in 74.76%, 9.71% and 15.53% of patients respectively. Nearly 52.4% of patients had  
35 a co-morbidity, with hypertension being the most common (34%), followed by diabetes  
36 mellitus (21.4%) and ischemic heart disease (9.7%). Fever (78.6%), weakness (68%) and  
37 cough (44.7%) were the most common clinical manifestations. Other common symptoms  
38 included loss of appetite (37.9%), difficulty in breathing (37.9%), altered sensation of taste or  
39 smell (35.0%), headache (32%) and body ache (32%). The median time from onset of  
40 symptom to attending hospitals was 7 days (IQR 4-10). This study will help both the  
41 clinicians and epidemiologists to understand the magnitude and clinical spectrum of COVID-  
42 19 patients in Bangladesh.

43

## 44 **Introduction**

45 The world has been experiencing one of the most serious public health crises in the history of  
46 humankind. The ongoing pandemic of coronavirus disease 2019 (COVID-19) is caused by  
47 severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). As of 28 July 2020, over 16

48 million individuals have been infected with over 650,000 deaths worldwide<sup>1</sup>. SARS-COV-2  
49 infection predominantly results in an acute respiratory illness. In addition, it can cause a  
50 myriad of extrapulmonary symptoms. The clinical spectrum ranges from asymptomatic or  
51 mildly symptomatic flu-like illness to potentially life-threatening critical conditions<sup>2</sup>. Recent  
52 studies suggest that the clinical spectrum of COVID-19 can vary among different ethnicities  
53 and geographical locations across the world<sup>3</sup>.

54

55 Owing to a population of over 160 million, inadequate healthcare system, and poor personal  
56 hygiene among the general population, Bangladesh is considered one of the high-risk  
57 countries for coronavirus spread. The first official case of COVID-19 was reported on 8  
58 March 2020, and the epidemic still appears to be in a growing phase. As of 30 July 2020, a  
59 total of 234,889 cases and 3083 deaths have been reported in Bangladesh<sup>1</sup>. However, the  
60 information on clinical manifestations from Bangladesh is scarce in the literature. Therefore,  
61 this study aimed to document the clinical spectrum of COVID-19 patients attending fever  
62 clinics in Bangladesh.

63

## 64 **Methods**

65 This was a cross-sectional study conducted among RT-PCR confirmed COVID-19 patients  
66 attending the fever clinic of a dedicated COVID-19 Hospital (Kurmitola general hospital) in  
67 Dhaka city of Bangladesh and two Upazila health complexes from different districts (Jessore  
68 and Jhenaidah) from 5 July to 18 July 2020. Diagnosis of SARS-COV-2 infection and  
69 assessment of severity were done based on the WHO interim guidance<sup>4</sup>. Data were collected  
70 only from non-critical COVID-19 patients as critical patients required immediate intensive  
71 care admission making them unable to respond to the questions. Socio-demographic and  
72 clinical data were evaluated and collected by experienced clinicians using a pretested case

73 record form. Verbal consent was taken from all participants. The institutional review board of  
74 Biomedical Research Foundation, Bangladesh approved the study protocol (Ref. no:  
75 BRF/ERB/2020/003).

76

77 Data were analysed by SPSS Statistics software 22.0 (Armonk, NY: IBM Corp). Data were  
78 expressed in number (percentages, %) and median (interquartile range, IQR) as appropriate.

79 We used Pearson's chi square test, Fisher's exact test and Kruskal Wallis test to compare  
80 differences between mild, moderate and severe patients where appropriate. Logistic  
81 regression was used to study associations.  $P < 0.5$  was set as statistically significant.

82

### 83 **Results**

84 A total of 103 laboratory-confirmed COVID-19 patients were enrolled. About 75% (77) of  
85 cases presented with mild symptoms, followed by nearly 15% severe and 10% moderate  
86 cases. Overall, the median age of the participants was 37 years (IQR: 31-53); more than 80%  
87 of these patients were under 60 years (Table 1). Most of the patients were male (71.8%).  
88 More than half of the patients (52.4%) had at least one co-morbidity, including hypertension  
89 in 35 (34%), diabetes mellitus in 22 (21.4%) and ischaemic heart disease in 10 (9.7%)  
90 patients. Notably, around 80% of moderate and severe cases had comorbidity. The median  
91 time from onset of symptom to attending fever clinic was 7 days (IQR 4-10).

92

93 Overall, the most common symptoms reported were fever (78.6%), weakness (68%) and  
94 cough (44.7%) followed by loss of appetite (37.9%), difficulty in breathing (37.9%), altered  
95 sensation of taste or smell (35.0%), headache (32%) and body ache (32%). Less common  
96 symptoms included sore throat (28.2%), diarrhoea (22.3%) and chest pain (14.6%). Fever  
97 was the most prevalent symptom in all groups of patients. Interestingly, 80% of moderate

98 patients experienced difficulty in breathing compared to 62.5% severe patients (Table 2).  
99 More than half of the severe cases had tachycardia (56.3%) and tachypnoea (56.3%) at  
100 presentation; their median oxygen saturation was 87.5% (IQR 77.25-89.0).

101

## 102 **Discussion**

103 This study aimed to determine the clinical characteristics of RT-PCR confirmed noncritical  
104 patients with COVID-19 attending fever clinics of government hospitals in Bangladesh.

105

106 The most prevalent symptoms of non-critical COVID-19 patients in Bangladesh consist of  
107 fever (78.6%), fatigue (68%) and cough (44.7%). Similarly, in a meta-analysis from China,  
108 most prevalent symptoms were fever (80.4%), cough (63.1%) and fatigue (46%)<sup>5</sup>. However,  
109 studies from China included both critical and non-critical patients. In contrast, one study from  
110 Europe on mild to moderate patients reported that headache (70.3%), loss of smell (70.2%),  
111 nasal obstruction (67.8%) were the most common symptoms; fever was reported by only  
112 45.4% of patients. Interestingly, 39% of mild cases, 40% of moderate cases and 12.5% of  
113 severe cases reported the altered sensation of taste or smell in this study. While olfactory and  
114 gustatory dysfunctions were prevalent symptoms in European patients, they were only rarely  
115 reported in Chinese patients<sup>6,7</sup>.

116

117 In this study, about 15% of cases were presented with severe symptoms. This is consistent  
118 with a summary report of 72,314 cases from China<sup>8</sup>. As expected, most of the severe patients  
119 (81.3%) had co-morbidity. Age >60 years, patients with diabetes mellitus, ischemic heart  
120 disease and chronic kidney disease had significantly higher odds of developing severe disease  
121 at presentation (Suppl. Table 1).

122

123 Our study has some limitations. First, the sample size of this study was small. Second, we  
124 could not include critical patients due to the requirement of emergency management.  
125 Therefore, our findings could not be generalized in the context of Bangladesh.

126

127 Our study reports the presenting symptoms of SARS-COV-2 infections among the  
128 Bangladeshi population. Although there are certain similarities in the range of symptoms with  
129 the Chinese population, where the pandemic originated, there are some unique findings like  
130 the high prevalence of olfactory and gustatory dysfunctions. This study will help both the  
131 clinicians and epidemiologists to understand the magnitude and clinical spectrum of COVID-  
132 19 patients in Bangladesh.

133

#### 134 **Conflict of interest**

135 None of the authors has any conflict of interest to declare

136

#### 137 **Author contribution**

138 MSM, MSH and AAM designed the study, gave professional guidance and wrote the  
139 manuscript. MSM, PC and SMA collected and analysed data.

140

#### 141 **Acknowledgement**

142 We are grateful to Brigadier General Jamil Ahmad, director, Kurmitola General Hospital  
143 (KGH); Dr. Tania Easmin, medical officer, KGH; Dr. Md. Rashed Al Mamun, upazilla health  
144 and family planning officer (UHFPO), Shailkupa, Jhenaidah and Dr. Md. Alamgir, UHFPO,  
145 Keshabpur, Jessore for their generous support in data collection.

146

#### 147 **Funding**

148 Not applicable

149

150 **References**

- 151 1. World Health Organization. Coronavirus disease (COVID-19) situation report-190, 28  
152 July, 2020. [https://www.who.int/docs/default-source/coronaviruse/situation-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200728-covid-19-sitrep-190.pdf?sfvrsn=fec17314_2)  
153 [reports/20200728-covid-19-sitrep-190.pdf?sfvrsn=fec17314\\_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200728-covid-19-sitrep-190.pdf?sfvrsn=fec17314_2). Accessed July 29,  
154 2020
- 155 2. Zhai P, Ding Y, Wu X, Long J, Zhong Y and Li Y. The epidemiology, diagnosis and  
156 treatment of COVID-19. *Int J Antimicrob Agents*. 2020;55(5):105955.  
157 [doi:10.1016/j.ijantimicag.2020.105955](https://doi.org/10.1016/j.ijantimicag.2020.105955)
- 158 3. Pan D, Sze S, Minhas JS, et al. The impact of ethnicity on clinical outcomes in  
159 COVID-19: A systematic review. *E Clin Med*. 2020:100404.  
160 <https://doi.org/10.1016/j.eclinm.2020.100404>
- 161 4. World Health Organization, clinical management of COVID-19, interim guidance, 27  
162 May 2020. [https://apps.who.int/iris/bitstream/handle/10665/332196/WHO-2019-nCoV-](https://apps.who.int/iris/bitstream/handle/10665/332196/WHO-2019-nCoV-clinical-2020.5-eng.pdf)  
163 [clinical-2020.5-eng.pdf](https://apps.who.int/iris/bitstream/handle/10665/332196/WHO-2019-nCoV-clinical-2020.5-eng.pdf). Accessed August 2, 2020.
- 164 5. Zhu J, Ji P, Pang J, et al. Clinical characteristics of 3062 COVID-19 patients: A  
165 meta-analysis. *J Med Virol*. 2020. <https://doi.org/10.1002/jmv.25884>
- 166
- 167 6. Lechien JR, Chiesa-Estomba CM, Place S, et al. Clinical and epidemiological  
168 characteristics of 1420 European patients with mild-to-moderate coronavirus disease  
169 2019. *J Intern Med*. 2020. <https://doi.org/10.1111/joim.13089>
- 170 7. Lechien JR, Chiesa-Estomba CM, De Sisti DR, et al. Olfactory and gustatory  
171 dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus  
172 disease (COVID-19): a multicenter European study. *Eur Arch Otorhinolaryngol*.  
173 2020;277(8):2251-2261. [doi:10.1007/s00405-020-05965-1](https://doi.org/10.1007/s00405-020-05965-1)

174

- 175        8. Wu Z and McGoogan JM. Characteristics of and Important Lessons From the  
176            Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of  
177            72□314 Cases From the Chinese Center for Disease Control and Prevention  
178            [published online ahead of print, 2020 Feb 24]. *JAMA*. 2020;10.  
179            [doi:10.1001/jama.2020.2648](https://doi.org/10.1001/jama.2020.2648)  
180



181 **List of Tables**

182

183 Table 1. Characteristics of patients with COVID-19 (N= 103)

184

Variables	Severity of patients with COVID-19				p
	Total n (%)	Mild	Moderate	Severe	
Patients' number	103 (100)	77 (74.76)	10 (9.71)	16 (15.53)	
Age (years), median (IQR)	37.0 (31.0, 53.0)	35.0 (29.0, 45.0)	52.5 (38.0, 63.25)	62.5 (42.5, 65.0)	<b>&lt;0.001*</b>
<b>Age group</b>					
≤60 years	84 (81.6)	70 (90.9)	7 (70.0)	7 (43.8)	<b>&lt;0.001</b>
>60 years	19 (18.4)	7 (9.1)	3 (30.0)	9 (56.3)	
<b>Gender</b>					
Male	74 (71.8)	55 (71.4)	9 (90.0)	10 (62.5)	0.38
Female	29 (28.2)	22 (28.6)	1 (10.0)	6 (37.5)	
<b>Area of residence</b>					
Urban	69 (67)	51 (66.2)	6 (60.0)	12 (75.0)	0.73
Rural	34 (33.0)	26 (33.8)	4 (40.0)	4 (25.0)	
<b>Smoking habit</b>					
Smokers	32 (31.1)	25 (32.5)	3 (30.0)	4 (25.0)	0.94
Nonsmokers	71 (68.9)	52 (67.5)	7 (70.0)	12 (75.0)	
<b>Comorbidities</b>					
At least one comorbidity	54 (52.4)	33 (42.9)	8 (80.0)	13 (81.3)	<b>0.003</b>
Hypertension	35 (34.0)	22 (28.6)	4 (40.0)	9 (56.3)	0.09
Diabetes mellitus	22 (21.4)	10 (13.0)	4 (40.0)	8 (50.0)	<b>0.002</b>
Ischemic heart disease	10 (9.7)	4 (5.2)	2 (20.0)	4 (25.0)	<b>0.02</b>
Chronic kidney disease	8 (7.8)	3 (3.9)	1 (10.0)	4 (25.0)	<b>0.02</b>
Bronchial asthma	6 (5.8)	5 (6.5)	0 (0.0)	1 (6.3)	1.00
Chronic obstructive pulmonary disease	3 (2.9)	1 (1.3)	1 (10.0)	1 (6.3)	0.16
**Others	16 (15.5)	11 (14.3)	1 (10.0)	4 (25.0)	0.53

185

186 Within parentheses are percentages over column total of respective variable

187 Pearson's chi square test/ Fisher's exact test was done as appropriate \*Kruskal Wallis test was done

188

189 \*\* Other comorbidities: Cerebrovascular disease 3 (2.9%), dyslipidemia 3 (2.9%), acute kidney injury 2 (1.9%), chronic liver  
190 disease 2 (1.9%), malignancy 1 (1.0%), Graves' thyrotoxicosis 1 (1.0%), nonalcoholic fatty liver disease 1 (1.0%), benign  
191 enlargement of prostate 1 (1.0%), allergic rhinitis 1 (1.0%), schizophrenia 1 (1.0%)

192

193

194

195 Table 2. Clinical features of patients with COVID-19 at presentations (N= 103)

196

Variables	Total n (%)	Severity of COVID-19			p
		Mild	Moderate	Severe	
Onset of symptom to consultation (days), median (IQR)	7.0 (4.0, 10.0)	7.0 (3.0, 10.0)	10.0 (6.75, 12.0)	9.5 (6.25, 10.0)	0.09*
<b>Symptoms</b>					
Fever	81 (78.6)	57 (74.0)	10 (100.0)	14 (87.5)	0.13
Weakness/ fatigue	70 (68.0)	52 (67.5)	6 (60.0)	12 (75.0)	0.73
Cough	46 (44.7)	34 (44.2)	5 (50.0)	7 (43.8)	0.95
Loss of appetite	39 (37.9)	26 (33.8)	7 (70.0)	6 (37.5)	0.10
Difficult breathing	39 (37.9)	21 (27.3)	8 (80.0)	10 (62.5)	<b>&lt;0.001</b>
Altered smell/ taste	36 (35.0)	30 (39.0)	4 (40.0)	2 (12.5)	0.10
Headache	33 (32.0)	25 (32.5)	3 (30.0)	5 (31.3)	1.00
Bodyache	33 (32.0)	23 (29.9)	5 (50.0)	5 (31.3)	0.43
Sore throat	29 (28.2)	27 (35.1)	0 (0.0)	2 (12.5)	<b>0.02</b>
Diarrhea	23 (22.3)	18 (23.4)	1 (10.0)	4 (25.0)	0.73
Chest pain	15 (14.6)	13 (16.9)	2 (20.0)	0 (0.0)	0.14
Runny nose	12 (11.7)	9 (11.7)	1 (10.0)	2 (12.5)	1.00
Chill	11 (10.7)	8 (10.4)	0 (0.0)	3 (18.8)	0.35
Others	23 (22.3)	17 (22.1)	1 (10.0)	5 (31.3)	0.43
<b>Signs at presentation</b>					
Tachycardia (pulse>100 beats/ minute)	37 (35.9)	26 (33.8)	2 (20.0)	9 (56.3)	0.13
Fever (T >38°C)	16 (15.5)	12 (15.6)	1 (10.0)	3 (18.8)	0.90
Tachypnea (respiratory rate >24 breaths/ minute)	11 (10.7)	0 (0.0)	2 (20.0)	9 (56.3)	<b>&lt;0.001</b>
Systolic blood pressure (mm-Hg), median (IQR)	120 (110, 136)	120 (110, 130)	125 (113.5, 140)	138 (120, 148.8)	<b>0.02*</b>
Oxygen saturation (%), median (IQR)	96.0 (93.0, 98.0)	97.0 (95.0, 98.0)	93.0 (91.75, 98.0)	87.5 (77.25, 89.0)	<b>&lt;0.001*</b>

197 Within parentheses are percentages over column total of respective variable, Pearson's chi square test/ Fisher's exact test  
 198 was done as appropriate \*Kruskal Wallis test was done  
 199

200 **Other symptoms:** Vomiting 8 (7.8%), abdominal pain 6 (5.8%), dizziness 5 (4.9%), red eye 4 (3.9%)  
 201  
 202  
 203  
 204

205 **Supplementary materials**

206

207 Suppl. Table 1. Binary logistic regression analysis to predict the severe disease at  
208 presentation

209

<b>Covariates</b>	<b>OR (95% CI)</b>	<b>p</b>
Age >60 years	9.90 (3.02, 32.45)	<b>&lt;0.001</b>
Diabetes mellitus	5.21 (1.68, 16.22)	<b>0.004</b>
Ischemic heart disease	4.50 (1.11, 18.30)	<b>0.04</b>
Chronic kidney disease	6.92 (1.52, 31.38)	<b>0.01</b>

210 CI, confidence interval; OR, odds ratio

211 Reference category is nonsevere illness (mild and moderate disease)

212

213

214

215